Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report
…
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Sangamo Therapeutics is a clinical-stage biotechnology company developing genomic therapies using zinc finger nuclease (ZFN) technology for gene editing, gene regulation and engineered cell therapies. Long-term growth may be driven by clinical progress in lead programs, potential durable one-time treatments and platform scalability that could support collaborations, which may appeal to investors seeking exposure to differentiated gene-editing approaches.
Key investment risks include ongoing clinical and regulatory uncertainty, no approved products requiring additional capital, competition from other gene-editing platforms, and execution risk in manufacturing and commercialization.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| SGMOQ Sangamo Therapeutics, Inc. |
- -% |
0.11 | - | - | - | - |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →Last updated on Nov 19, 2026 03:41 PM AEDT
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Last updated on Nov 19, 2026 04:48 PM AEDT
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Hi! How can we help you today?
Loading…